- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Intravitreal Aflibercept Injection 2mg
- Drug
- Lead sponsor
- Tennessee Retina
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 159
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- 0.5 mg Conbercept Intravitreal Injection, 1.0 mg Conbercept Intravitreal Injection, 2.0 mg Aflibercept Intravitreal Injection
- Biological
- Lead sponsor
- Chengdu Kanghong Biotech Co., Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 63
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- REGN2176-3, Intravitreal Aflibercept Injection (IAI)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 505 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 75
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 72 more
- Conditions
- Choroidal Neovascularization, Presumed Ocular Histoplasmosis
- Interventions
- EYLEA (Aflibercept) intravitreal injection
- Drug
- Lead sponsor
- Retina Research Institute, LLC
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 3
- States / cities
- St Louis, Missouri
- Conditions
- Central Serous Chorioretinopathy
- Interventions
- Intravitreal Aflibercept Injection
- Drug
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- Huntingdon Valley, Pennsylvania • Philadelphia, Pennsylvania
- Conditions
- AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy)
- Interventions
- Alfilbercept
- Drug
- Lead sponsor
- Vitreous -Retina- Macula Consultants of New York
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization
- Interventions
- Brolucizumab ophthalmic solution, Aflibercept ophthalmic solution
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,775 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Diabetic Macular Edema
- Interventions
- Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321), Macular Laser Photocoagulation
- Drug · Procedure
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 466 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 51
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 48 more
- Conditions
- Exudative Macular Degeneration
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- Rishi Singh
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- GB-102, Aflibercept
- Drug
- Lead sponsor
- Graybug Vision
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 8
- States / cities
- Gilbert, Arizona • Beverly Hills, California • Indianapolis, Indiana + 5 more
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- Aflibercept High Dose VEGF Trap-Eye (BAY86-5321), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,011 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 57
- States / cities
- Phoenix, Arizona • Fullerton, California • Mountain View, California + 52 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Aflibercept, Triamcinolone Acetonide, Verteporfin
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 55 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Diabetic Macular Edema
- Interventions
- Iluvien 0.19 MG Drug Implant, Aflibercept
- Drug
- Lead sponsor
- Alimera Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 36 more
- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 568 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 81
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Fresno, California + 75 more
- Conditions
- Neovascular Age-related Macular Degeneration, nAMD
- Interventions
- ABP 938 8 mg, Aflibercept (US) 8 mg
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 54
- States / cities
- Fullerton, California • Long Beach, California • Modesto, California + 49 more
- Conditions
- Wet Age-related Macular Degeneration
- Interventions
- Intravitreal anti-VEGF, Intravitreal AAVCAGsCD59, Oral prednisolone
- Drug · Biological
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Worcester, Massachusetts
- Conditions
- Diabetic Macular Edema
- Interventions
- Ozurdex, Eylea
- Drug
- Lead sponsor
- Texas Retina Associates
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus, Diabetic Retinopathy, Retinal Degeneration, Retinal Diseases, Eye Diseases, Edema
- Interventions
- Aflibercept, foselutoclax
- Drug
- Lead sponsor
- Unity Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 19
- States / cities
- Bakersfield, California • Beverly Hills, California • Huntington Beach, California + 16 more
- Conditions
- Age-related Macular Degeneration (AMD)
- Interventions
- Aflibercept, Ranibizumab, Bevacizumab
- Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 369,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Retinopathy of Prematurity
- Interventions
- aflibercept, laser photocoagulation
- Drug · Procedure
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • La Jolla, California • Loma Linda, California + 21 more
- Conditions
- Wet Macular Degeneration
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 559 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 59
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 53 more
- Conditions
- Ocular Histoplasmosis
- Interventions
- aflibercept
- Drug
- Lead sponsor
- John Kitchens, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 3
- States / cities
- Augusta, Georgia • Lexington, Kentucky • Cincinnati, Ohio
- Conditions
- Diabetic Macular Edema
- Interventions
- Ranibizumab 0.3 mg, Aflibercept 2.0 mg
- Drug
- Lead sponsor
- Arshad Khanani
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Reno, Nevada
- Conditions
- Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
- Interventions
- Faricimab, Aflibercept, Sham Procedure
- Drug · Procedure
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 729 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 57
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 52 more